Argentina Develops Next-Generation Vaccines Against Bovine Paralytic Rabies

Argentine Scientists Lead Progress ⁣of Next-Generation Rabies Vaccines

Breakthrough Could Protect ‍Livestock and Humans from Deadly Disease

Argentine researchers are making strides in the fight against rabies, a deadly viral‍ disease that affects both animals and humans. A⁤ team of​ specialists from the National Institute of Agricultural technology (INTA) and ⁢the National governance of Laboratories and Health Institutes Dr. Carlos G. Malbrán ⁢(ANLIS-Malbrán) are leading the development of cutting-edge, third-generation rabies vaccines.

These innovative vaccines, presented at the XXXV Rabies in the Americas‌ (RITA) Congress, promise a more robust and long-lasting immune response compared to currently available vaccines.

“We are very excited⁤ about the results obtained so far,”‍ said María Paula Del‌ Médico Zajac, a researcher at INTA ‌and CONICET. “We have developed very promising ‌vaccine candidates that have shown their effectiveness in preclinical trials.”

Rabies, a ⁢zoonotic disease, can‌ infect all mammals, including livestock and humans. Transmission occurs thru contact with infected saliva, typically through bites or scratches. While rabies is 100%⁢ preventable⁢ through vaccination,⁣ it remains a serious public health concern.The new vaccines utilize recombinant technology, eliminating the⁤ need to handle live⁤ rabies ‍virus during production. This substantially‍ enhances safety ⁤for both animals and humans.

“These candidates are based on safe viral vectors that do not spread in the vaccinated organism,” explained Del Médico Zajac.

The ⁣collaborative ⁤effort between the Pox and Adenovirus Vectorized vaccines group at ⁣the INTA Biotechnology Institute ‌and the Rabies Vaccine Service‌ at ANLIS-Malbrán is crucial to advancing this research.

Targeting a Persistent Threat

Rabies is endemic ​in many parts of the world, including Argentina. The ⁢vampire bat (Desmodus ⁤rotundus) is a primary transmitter of ‌the disease, primarily‌ affecting cattle, ‌horses, and other domestic animals.

Gabriela calamante, a researcher at the INTA‌ Biotechnology Institute and CONICET, emphasized the importance of a multi-pronged approach: “The development of biotechnological vaccines is a long process, ⁢so ⁢having a ⁤portfolio of different platforms allows us to advance on​ several fronts together.We are confident that these vaccines will have a positive impact on animal and human health.”

the RITA Congress provided a platform‍ for the Argentine researchers to share ⁢their findings with the international⁣ scientific community. Their presentation, “Development⁤ of Third-Generation Rabies ⁢Vaccines Based on Viral and Plasmid Vectors,” highlighted the progress made in developing various vaccine candidates and evaluating their effectiveness in preclinical models.

this groundbreaking research holds ‍immense potential for protecting livestock and humans from this deadly disease, underscoring the importance of continued investment in vaccine⁢ development and global health initiatives.

Argentine Scientists Lead Progress of Next-Generation Rabies Vaccines: ‍A Q&A with Maria⁣ Paula del Médico‍ Zajac

NewsDirect3.com: Argentina is at⁢ the forefront of rabies vaccine progress. Can ‍you⁤ tell us more about the innovative work being done by your team?

Dr. María paula Del Médico ⁤Zajac: We are developing third-generation‍ rabies vaccines using‍ cutting-edge recombinant⁤ technology. These vaccines hold the promise of a more robust and long-lasting immune response compared to existing vaccines.

NewsDirect3.com: What makes these new ‌vaccines so groundbreaking?

Dr. ‍Del Médico zajac: Our vaccine candidates are based on safe viral‍ vectors that do not spread within the vaccinated organism. This eliminates the need to work⁤ with live rabies virus during production, significantly enhancing safety​ for both animals and humans.

NewsDirect3.com: How does this work specifically combat⁢ the threat of rabies ‌in Argentina?

Dr.Del Médico Zajac: rabies is endemic in manny parts of Argentina, primarily transmitted by vampire bats. Our vaccines target this threat by providing ⁣effective protection for⁣ cattle, horses, ⁣and‍ other ​domestic ⁤animals, ultimately reducing the​ risk of​ transmission to humans.

NewsDirect3.com: What stage of development are these vaccines in currently?

Dr. Del Médico Zajac: We have seen very promising results in preclinical trials. ⁣The next step⁤ involves further testing and evaluation to ensure safety and efficacy before moving towards human clinical trials.

NewsDirect3.com: This collaborative effort‍ between INTA and ANLIS-Malbrán seems crucial to the success of this project. Can you elaborate ‌on ‌the importance of these partnerships?

Dr.Del Médico ⁢Zajac: Absolutely. The collaboration‌ between the ⁣Pox and Adenovirus ⁢Vectorized vaccines group at the INTA​ Biotechnology Institute ⁣and⁤ the Rabies Vaccine Service⁣ at ANLIS-Malbrán brings together expertise in virology, vaccinology, and⁣ public health, which is essential ​for developing effective and accessible vaccines.

NewsDirect3.com: What is‍ the potential impact of these vaccines on a global ⁢scale?

Dr.Del Médico Zajac: Rabies ⁤is a global health concern.Our research not only has the potential to drastically reduce the incidence of rabies in Argentina but also serves as a⁣ model for other countries facing similar challenges. By sharing⁢ our findings with‍ the international scientific community, we hope to contribute to a world⁣ free from rabies.